Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FAZA PET and Multiparametric MR in High Grade Glioma and Cervical Cancers
NCT05047913Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]FluorThanatrace in high-grade glioma (HGG) and Cervical Cancer (CC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Correlation between dynamic MRI (tumor perfusion and permeability) and dynamic 18F-FAZA PET uptake at 1 year. Started Sep 2021; status: active, not recruiting.
02
Drugs
[18F]FluorThanatrace
03
Conditions
high-grade glioma (HGG)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05047913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047913.